Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,062Revenue $M49.0Net Margin (%)12.2Z-Score0.5
Enterprise Value $M1,068EPS $0.6Operating Margin %29.2F-Score6
P/E(ttm))167Cash Flow Per Share $0.6Pre-tax Margin (%)11.2Higher ROA y-yN
Price/Book24.010-y EBITDA Growth Rate %0Quick Ratio10.7Cash flow > EarningsY
Price/Sales20.25-y EBITDA Growth Rate %0Current Ratio10.8Lower Leverage y-yN
Price/Cash Flow32.1y-y EBITDA Growth Rate %36.9ROA % (ttm)5.0Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)8ROE % (ttm)12.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M20.8ROI % (ttm)10.2Gross Margin Increase y-yY

Gurus Latest Trades with LGND

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LGNDJoel Greenblatt 2014-09-30 Add0.23%$46.99 - $64.52
($53.04)
$ 53.050%Add 894.83%552,053
LGNDJoel Greenblatt 2014-06-30 Buy 0.04%$59.74 - $70.19
($65.09)
$ 53.05-18%New holding, 55492 sh.55,492
LGNDKen Fisher 2014-06-30 Buy $59.74 - $70.19
($65.09)
$ 53.05-18%New holding, 36908 sh.36,908
LGNDJoel Greenblatt 2014-03-31 Sold Out -0.02%$51.52 - $79.58
($66.37)
$ 53.05-20%Sold Out0
LGNDJoel Greenblatt 2013-12-31 Add0.01%$44.86 - $57.95
($52.33)
$ 53.051%Add 124.95%13,803
LGNDJoel Greenblatt 2013-09-30 Buy 0.01%$38.69 - $49.66
($45.21)
$ 53.0517%New holding, 6136 sh.6,136
LGNDDaniel Loeb 2011-12-31 Sold Out -0.46%$10.59 - $15.73
($12.77)
$ 53.05315%Sold Out0
LGNDGeorge Soros 2011-09-30 Sold Out -0.0017%$10.89 - $15.95
($13.18)
$ 53.05302%Sold Out0
LGNDDaniel Loeb 2011-06-30 Add0.16%$9.56 - $12.02
($10.55)
$ 53.05403%Add 110.73%705,016
LGNDGeorge Soros 2011-06-30 Buy $9.56 - $12.02
($10.55)
$ 53.05403%New holding, 10000 sh.10,000
LGNDGeorge Soros 2009-12-31 Sold Out $9.96 - $14.16
($12.06)
$ 53.05340%Sold Out0
LGNDGeorge Soros 2009-09-30 Buy $13.74 - $18.9
($16.26)
$ 53.05226%New holding, 26900 sh.26,900
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LGND is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
LGND Joel Greenblatt 2014-09-30552,0532.660.26+894.83%
LGND Ken Fisher 2014-09-3035,2580.170-4.47%
Premium Most recent portfolio changes are included for Premium Members only!


LGND: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KOZARICH JOHN WDirector 2014-10-15Buy2,000$45.6816.13view
FOEHR MATTHEW WEVP and COO 2014-10-10Buy85$44.9118.13view
KNOTT DAVID MDirector 2014-10-09Buy4,000$43.0123.34view
Sabba Stephen LDirector 2014-10-09Buy2,000$43.1223.03view
Aryeh JasonDirector 2014-10-09Buy11,000$42.9923.4view
HIGGINS JOHN LPresident & CEO 2014-08-15Buy1,000$54.97-3.49view
FOEHR MATTHEW WEVP and COO 2014-06-30Buy428$43.7921.15view
Berkman Charles SVP, Gen. Counsel & Secretary 2014-06-30Buy329$43.7921.15view
Herman Melanie JDirector of Accounting 2014-06-30Buy98$43.7921.15view
Herman Melanie JDirector of Accounting 2014-06-09Sell1,100$69.68-23.87view

Press Releases about LGND :

    Quarterly/Annual Reports about LGND:

    News about LGND:

    Articles On GuruFocus.com
    Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
    5 Hot Stocks to Consider Now Mar 30 2012 
    Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
    Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
    Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
    Ligand to Acquire Neurogen for Stock and Contingent Value Rights Aug 24 2009 
    Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 
    Ligand Pharmaceuticals Announces Second Quarter Results Aug 03 2009 
    Ligand Announces Fourth Quarter and Full Year 2008 Consolidated Financial Results Feb 12 2009 
    Ligand to Hold Fourth Quarter Results Conference Call on February 12 Jan 29 2009 


    More From Other Websites
    Lemelson Capital Management CIO Discusses Ligand Pharmaceuticals Prior To Company Issuing Weak... Nov 18 2014
    Ligand Provides Highlights from Today’s Analyst Day Event Nov 18 2014
    LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure Nov 18 2014
    Ligand/Glaxo Seek EU Nod for Severe Aplastic Anemia Drug Nov 13 2014
    Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia... Nov 12 2014
    Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia... Nov 12 2014
    10-Q for Ligand Pharmaceuticals, Inc. Nov 03 2014
    LIGAND PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Oct 31 2014
    Twitter gives out 47% of its revenue in stock bonuses Oct 29 2014
    Ligand Pharmaceuticals' Shares Fall on Q3 Earnings Miss Oct 29 2014
    Ligand Reports Third Quarter 2014 Financial Results Oct 27 2014
    Ambaraella, Pier One, Pfizer, Teva Pharmaceutical and Ligand Pharmaceuticals highlighted as Zacks... Oct 27 2014
    Ligand beats Street 3Q forecasts Oct 27 2014
    Ligand beats Street 3Q forecasts Oct 27 2014
    LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Oct 27 2014
    Ligand Reports Third Quarter 2014 Financial Results Oct 27 2014
    Q3 2014 Ligand Pharmaceuticals Inc Earnings Release - Before Market Open Oct 27 2014
    Ligand to Report Third Quarter 2014 Financial Results Oct 27 2014
    Will Ligand Pharmaceuticals Beat Q3 Earnings Estimates? Oct 24 2014
    Will Vertex Pharmaceuticals (VRTX) Post a Lower Q3 Loss? Oct 24 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK